期刊文献+
共找到292篇文章
< 1 2 15 >
每页显示 20 50 100
Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice 被引量:3
1
作者 Shomron Ben-Horin Jane M Andrews +14 位作者 Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein 《World Journal of Gastroenterology》 SCIE CAS 2017年第16期2995-3002,共8页
AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(... AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P < 0.001), and 11(3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340(41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most(94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients. 展开更多
关键词 Inflammatory bowel disease CORTICOSTEROIDS 5-aminosalicylates Ulcerative colitis
下载PDF
Efficacy of Topical versus Oral 5-Aminosalicylate for Treatment of 2,4,6-Trinitrobenzene Sulfonic Acid-induced Ulcerative Colitis in Rats 被引量:3
2
作者 李进 陈成 +3 位作者 曹小年 王桂华 胡俊波 王晶 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2014年第1期59-65,共7页
5-aminosalicylic acid(5-ASA) is drug of choice for the treatment of ulcerative colitis(UC). In this study, the efficacy of topical versus oral 5-ASA for the treatment of UC was examined as well as the action mecha... 5-aminosalicylic acid(5-ASA) is drug of choice for the treatment of ulcerative colitis(UC). In this study, the efficacy of topical versus oral 5-ASA for the treatment of UC was examined as well as the action mechanism of this medication. A flexible tube was inserted into the rat cecum to establish a topical administration model of 2,4,6-trinitrobenzene sulfonic acid(TNBS)-induced UC. A total of 60 rats were divided into sham operation group(receiving an enema of 0.9% saline solution instead of the TNBS solution via the tube), model group, topical 5-ASA group, oral Etiasa group(a release agent of mesalazine used as positive control) and oral 5-ASA group(n=12 each). Different treatments were administered 1 day after UC induction. The normal saline(2 mL) was instilled twice a day through the tube in the sham operation group and model group. 5-ASA was given via the tube in the topical 5-ASA group(7.5 g/L, twice per day, 100 mg/kg), and rats in the oral Etiasa group and oral 5-ASA group intragastrically received Etiasa(7.5 g/L, twice per day, 100 mg/kg) and 5-ASA(7.5 g/L, twice per day, 100 mg/kg), respectively. The body weight was recorded every day. After 7 days of treatment, blood samples were drawn from the heart to harvest the sera. Colonic tissues were separated and prepared for pathological and related molecular biological examinations. The concentrations of 5-ASA were detected at different time points in the colonic tissues, feces and sera in different groups by using the high pressure liquid chromatography(HPLC). The results showed that the symptoms of acute UC, including bloody diarrhea and weight loss, were significantly improved in topical 5-ASA-treated rats. The colonic mucosal damage, both macroscopical and histological, was significantly relieved and the myeloperoxidase activity was markedly decreased in rats topically treated with 5-ASA compared with those treated with oral 5-ASA or Etiasa. The mRNA and protein expression of IL-1β, IL-6, and TNF-α was down-regulated in the colonic tissue of rats topically treated with 5-ASA, significantly lower than those from rats treated with oral 5-ASA or Etiasa. The concentrations of 5-ASA in the colonic tissue were significantly higher in the topical 5-ASA group than in the oral 5-ASA and oral Etiasa groups. It was concluded that the topical administration of 5-ASA can effectively increase the concentration of 5-ASA in the colonic tissue, decrease the expression of proinflammatory cytokines, alleviate the colonic pathological damage and improve the symptoms of TNBS-induced acute UC in rats. 展开更多
关键词 ulcerative colitis 5-aminosalicylic acid 2 4 6-trinitrobenzene sulfonic acid
下载PDF
Synthesis of Chromium (Ⅲ) 5-aminosalicylate
3
作者 LI Wei HAO Er-jun JIANG Yu-qin 《合成化学》 CAS CSCD 2004年第z1期71-71,共1页
关键词 5- ASA chromium CHROMIUM (Ⅲ) 5-aminosalicylate
下载PDF
5-Aminosalicylates to maintain remission in Crohn's disease:Interpreting conflicting systematic review evidence
4
作者 Morris Gordon 《World Journal of Gastrointestinal Pharmacology and Therapeutics》 CAS 2017年第2期99-102,共4页
5-Aminosalicylates are a class of anti-inflammatory agents that have been used for decades in inflammatory bowel disease. Whilst they are first line for induction and anoption for maintenance of remission in ulcerativ... 5-Aminosalicylates are a class of anti-inflammatory agents that have been used for decades in inflammatory bowel disease. Whilst they are first line for induction and anoption for maintenance of remission in ulcerative colitis, the picture in Crohn's disease is variable. For maintenance of remission, key Cochrane systematic reviews have found conflicting results between the medical and surgical induced contexts. In this piece, the possible reasons for this are considered. It is proposed that clinicians should consider 5-aminosalicylates agents an option to maintain remission post-surgery. Future primary research is needed in the medical induced remission setting which considers the length of remission on enrolment and endoscopic or histological disease scores. Additionally, secondary research to rank the various treatment options in the post-surgical setting could be achieved through the use of network meta-analysis and will guide policy makers in the future. 展开更多
关键词 5-aminosalicylate Systematic review Crohn’s disease Inflammatory bowel disease COCHRANE
下载PDF
脓毒症并发急性肾损伤患者血清HDAC4和KLF5的表达及其临床价值
5
作者 李玉伟 王瑾 +1 位作者 乔薇 王助衡 《中国急救复苏与灾害医学杂志》 2024年第3期359-363,共5页
目的探究脓毒症并发急性肾损伤(AKI)患者血清组蛋白去乙酰基转移酶4(HDAC4)和锌指蛋白转录因子5(KLF5)表达及临床价值。方法选取2020年9月—2022年9月本院收治的60例脓毒症并发AKI患者作为AKI组,选取同期北京市大兴区人民医院收治的75... 目的探究脓毒症并发急性肾损伤(AKI)患者血清组蛋白去乙酰基转移酶4(HDAC4)和锌指蛋白转录因子5(KLF5)表达及临床价值。方法选取2020年9月—2022年9月本院收治的60例脓毒症并发AKI患者作为AKI组,选取同期北京市大兴区人民医院收治的75例脓毒症未发生AKI患者作为非AKI组。比较两组的临床资料、血清HDAC4和KLF5水平。ROC分析血清HDAC4和KLF5对脓毒症患者并发AKI的诊断价值。Logistic回归分析影响脓毒症患者并发AKI的因素。结果与非AKI组相比,AKI组患者血清HDAC4、KLF5、降钙素原(PCT)、肌酐(Cr)、序贯性器官衰竭(SOFA)、急性生理学及慢性健康状况评分系统Ⅱ(APACHEⅡ)评分较高,AKI组血小板计数(PLT)较低,差异有统计学意义(P<0.05)。随着AKI组患者分期升高,血清HDAC4和KLF5水平依次升高,差异有统计学意义(P<0.05)。ROC曲线分析显示,血清HDAC4、KLF5可辅助诊断脓毒症患者是否并发AKI的曲线下面积(AUC)是0.800(95%CI:0.723~0.876)、0.810(95%CI:0.735~0.886);二者联合诊断的AUC为0.908(95%CI:0.856~0.961),均优于各自单独检测(Z=2.277、2.102,P<0.05)。Logistic回归分析显示,APACHEⅡ评分、SOFA评分、HDAC4、KLF5是影响脓毒症患者是否并发AKI的危险因素(P<0.05)。结论脓毒症并发AKI患者血清HDAC4、KLF5水平升高,且二者联合检测对脓毒症并发AKI的诊断效能较高,对评估脓毒症并发AKI有较好的临床诊断价值。 展开更多
关键词 脓毒症并发肾损伤 组蛋白去乙酰基转移酶4 锌指蛋白转录因子5 临床价值
下载PDF
miR-592靶向调控PRDM5影响肾细胞癌侵袭转移及自噬的机制研究
6
作者 李顺来 宋晓琳 +1 位作者 姜亭起 王文祯 《医学分子生物学杂志》 CAS 2024年第3期239-246,共8页
目的探究miR-592靶向调控PR结构域锌指蛋白5(PR domain zinc finger protein 5,PRDM5)影响肾细胞癌(renal cell carcinoma,RCC)侵袭转移及自噬的机制。方法RT-qPCR、蛋白质印迹检测RCC组织和细胞中miR-592、PRDM5 mRNA和蛋白水平。A498... 目的探究miR-592靶向调控PR结构域锌指蛋白5(PR domain zinc finger protein 5,PRDM5)影响肾细胞癌(renal cell carcinoma,RCC)侵袭转移及自噬的机制。方法RT-qPCR、蛋白质印迹检测RCC组织和细胞中miR-592、PRDM5 mRNA和蛋白水平。A498、786-O细胞分为anti-miR-NC组、anti-miR-592组、anti-miR-592+si-NC组、anti-miR-592+si-PRDM5组。RNA免疫共沉淀(RIP)检测miR-592和PRDM5的结合;CCK-8、Transwell实验检测细胞增殖、迁移和侵袭能力;透射电镜观察自噬小体形成;蛋白质印迹检测细胞PRDM5、基质金属蛋白酶(MMP)-2、MMP-9、Beclin1、微管相关蛋白1轻链3(LC3)Ⅱ/Ⅰ水平。建立移植瘤裸鼠模型,分析敲低miR-592表达对移植瘤生长的影响。结果RCC组织和细胞中PRDM5 mRNA和蛋白水平降低,miR-592水平增加(P<0.05)。敲低miR-592表达后,细胞A_(450 nm)、迁移和侵袭细胞数、MMP-2、MMP-9水平降低,自噬小体数量、Beclin1、LC3Ⅱ/Ⅰ水平增加(P<0.05)。敲低PRDM5表达能部分逆转敲低miR-592对细胞增殖、侵袭及自噬的影响(P<0.05)。敲低miR-592表达能够抑制裸鼠移植瘤生长(P<0.05)。结论miR-592通过靶向抑制PRDM5表达,促进RCC细胞增殖、侵袭转移能力,并抑制自噬能力。 展开更多
关键词 miR-592 PR结构域锌指蛋白5 肾细胞癌 侵袭转移 自噬
下载PDF
Microproteinuria in patients with inflammatory bowel disease:Is it associated with the disease activity or the treatment with 5-aminosalicylic acid? 被引量:131
7
作者 Androniki C Poulou Konstantinos E Goumas +5 位作者 Dimitrios C Dandakis Ioannis Tyrmpas Maria Panagiotaki Androniki Georgouli Dimitrios C Soutos Athanasios Archimandritis 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第5期739-746,共8页
AIM: To investigate whether microproteinuria in patients with inflammatory bowel disease (IBD) is associated with the disease activity or the treatment with 5-aminosalicylic acid (5-ASA). METHODS: We prospective... AIM: To investigate whether microproteinuria in patients with inflammatory bowel disease (IBD) is associated with the disease activity or the treatment with 5-aminosalicylic acid (5-ASA). METHODS: We prospectively studied microproteinuria in 86 consecutive patients with IBD, 61 with ulcerative colitis (UC) and 25 with Crohn's disease (CD), before as well as 2 and 6 months after their inclusion in the study. Forty-six patients received 5-ASA for a period of 28.8 months (range 1-168 too). Microalbuminuria (mALB) and urine levels of the renal tubular proteins β2-microglobulin (β2mGLB) and β-N-acetyI-D-glucosamidase (β-NAG) as well as the creatinine clearance were determined in a 12-h overnight urine collection. Tumor necrosis factor-α (TNF-α) serum levels were also measured. RESULTS: A total of 277 measurements (194 in UC patients and 83 in CD patients) were performed. The prevalence of abnormal microoproteinuria in UC and CD patients was 12.9% and 6.0% for mALB, 22.7% and 27.7% for B2mGLB, and 11.3% and 8.4% for β-NAG, respectively, mALB was not associated with IBD activity. β2mGLB and B-NAG urine levels were correlated to UC activity (UCAI: P〈0.01; UCEI: P〈0.005). mALB in UC patients and β-NAG urine levels in CD patients were related to TNF-α serum levels. An association was noticed between microproteinuria and smoking habit. Treatment with 5-ASA was not correlated to the severity of microproteinuria or to the changes of creatinine clearance.CONCLUSION: Microproteinuria is mainly associated with UC and its activity but not affected by 5-ASA. 展开更多
关键词 Inflammatory bowel disease Microproteinuria 5-aminosalicylic acid
下载PDF
5-aminosalicylicacid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease 被引量:7
8
作者 YangCheng PierreDesreumaux 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第3期309-314,共6页
Inflammatory bowel disease (IBD) is classically subdivided into ulcerative colitis (UC) and Crohn's disease (CD). Patients with IBD have increased risk for colorectal cancer. Because the pathogenesis of colorectal... Inflammatory bowel disease (IBD) is classically subdivided into ulcerative colitis (UC) and Crohn's disease (CD). Patients with IBD have increased risk for colorectal cancer. Because the pathogenesis of colorectal carcinoma has not been entirely defined yet and there is no ideal treatment for colon cancer, cancer prevention has become increasingly important in patients with IBD. The two adopted methods to prevent the development of colon cancer in clinical practice include the prophylactic colectomy and colonoscopic surveillance.But patients and physicians seldom accept colectomy as a routine preventive method and most patients do not undergo appropriate colonoscopic surveillance. Chemoprevention refers to the use of natural or synthetic chemical agents to reverse, suppress, or to delay the process of carcinogenesis.Chemoprevention is a particularly useful method in the management of patients at high risk for the development of specific cancers based on inborn genetic susceptibility, the presence of cancer-associated disease, or other known risk factors. Prevention of colorectal cancer by administration of chemopreventive agents is one of the most promising options for IBD patients who are at increased risks of the disease. The chemopreventive efficacy of nonsteroidal antiinflammatory drugs (NSAIDs) against intestinal tumors has been well established. But with reports that NSAIDs aggravated the symptoms of colitis, their sustained use for the purpose of cancer chemoprevention has been relatively contraindicated in IBD patients. Another hopeful candidate chemoprevention drug for IBD patients is 5-aminosalicylic acid (5-ASA), which is well tolerated by most patients and has limited systemic adverse effects, and no gastrointestinal toxicity. 5-ASA lacks the well-known side effects of longterm NSAIDs use. Retrospective correlative studies have suggested that the long-term use of 5-ASA in IBD patients may significantly reduce the risk of development of colorectal cancer. According to the literature, this agent might well satisfy clinical expectations with respect to a safe and effective chemopreventive agent. 展开更多
关键词 Inflammatory bowel disease Colon cancer 5-aminosalicylic acid NSAIDS
下载PDF
Severe chest pain in a pediatric ulcerative colitis patient after 5-aminosalicylic acid therapy 被引量:6
9
作者 Orhan Atay Kadakkal Radhakrishnan +1 位作者 Janine Arruda Robert Wyllie 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第27期4400-4402,共3页
Severe reactions to mesalamine products are rarely seen in pediatric patients. We report a case of a 12-year-old boy who had a severe cardiac reaction to a mesalamine product Asacol. Past medical history is significan... Severe reactions to mesalamine products are rarely seen in pediatric patients. We report a case of a 12-year-old boy who had a severe cardiac reaction to a mesalamine product Asacol. Past medical history is significant for ulcerative colitis (UC) diagnosed at 9 years of age. Colo- noscopy one week prior to admission revealed pancoli- tis. He was treated with Asacol 800 mg three times per day and prednisone 20 mg/d. He was subsequently ad- mitted to the hospital for an exacerbation of his UC and started on intravenous solumedrol. He had improvement of his abdominal pain and diarrhea. The patient com- plained of new onset of chest pain upon initiating Asacol therapy. Electrocardiogram (ECG) revealed non-specific ST-T wave changes with T-wave inversion in the lateral leads. Echocardiogram (ECHO) revealed low-normal to mildly depressed left ventricular systolic function. The left main coronary artery and left anterior descending artery were mildly prominent measuring 5 mm and 4.7 mm, respectively. His chest pain completely resolved within 24-36 h of discontinuing Asacol. A repeat echo- cardiogram performed two days later revealed normal left ventricular function with normal coronary arteries (< 3.5 mm). Onset of chest pain after Asacol and im- mediate improvement of chest pain, as well as improve- ment of echocardiogram and ECG findings after discon- tinuing Asacol suggests that our patient suffered from a rare drug-hypersensitivity reaction to Asacol. 展开更多
关键词 MESALAMINE 5-aminosalicylic acid Ulcerative colitis PERICARDITIS Drug hypersensitivity reaction
下载PDF
Epstein-Barr virus is related with 5-aminosalicylic acid, tonsillectomy, and CD19^+ cells in Crohn's disease 被引量:3
10
作者 Juan C Andreu-Ballester Rafael Gil-Borrás +4 位作者 Carlos García-Ballesteros Ignacio Catalán-Serra Victoria Amigo Virgina Fernández-Fígares Carmen Cuéllar 《World Journal of Gastroenterology》 SCIE CAS 2015年第15期4666-4672,共7页
AIM: To study anti-Epstein-Barr virus(EBV) Ig G antibodies in Crohn′s disease in relation to treatment, immune cells, and prior tonsillectomy/appendectomy.METHODS: This study included 36 CD patients and 36 healthy in... AIM: To study anti-Epstein-Barr virus(EBV) Ig G antibodies in Crohn′s disease in relation to treatment, immune cells, and prior tonsillectomy/appendectomy.METHODS: This study included 36 CD patients and 36 healthy individuals(controls), and evaluated different clinical scenarios(new patient, remission and active disease), previous mucosa-associated lymphoid tissue removal(tonsillectomy and appendectomy) and therapeutic regimens(5-aminosalicylic acid, azathioprine, anti-tumor necrosis factor, antibiotics, and corticosteroids). T and B cells subsets in peripheral blood were analyzed by flow cytometry(markers included: CD45, CD4, CD8, CD3, CD19, CD56, CD2, CD3, TCRαβ and TCRγδ) to relate with the levels of anti-EBV Ig G antibodies, determined by enzyme-linked immunosorbent assay.RESULTS: The lowest anti-EBV Ig G levels were observed in the group of patients that were not in a specific treatment(95.4 ± 53.9 U/m L vs 131.5 ± 46.2 U/m L, P = 0.038). The patients that were treated with 5-aminosalicylic acid showed the highest anti-EBV Ig G values(144.3 U/m L vs 102.6 U/m L, P = 0.045). CD19+ cells had the largest decrease in the group of CD patients that received treatment(138.6 vs 223.9; P = 0.022). The analysis of anti-EBV Ig G with respect to the presence or absence of tonsillectomy showed the highest values in the tonsillectomy group of CD patients(169.2 ± 20.7 U/m L vs 106.1 ± 50.3 U/m L, P = 0.002). However, in the group of healthy controls, no differences were seen between those who had been tonsillectomized and subjects who had not been operated on(134.0 ± 52.5 U/m L vs 127.7 ± 48.1 U/m L, P = 0.523).CONCLUSION: High anti-EBV Ig G levels in CD are associated with 5-aminosalicylic acid treatment, tonsillectomy, and decrease of CD19+ cells. 展开更多
关键词 B CELLS Crohn's disease EPSTEIN-BARR virus TONSILLECTOMY 5-aminosalicylic acid
下载PDF
Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis:Is there anything new under the sun? 被引量:3
11
作者 Peter Laszlo Lakatos 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第15期1799-1804,共6页
5-aminosalicylate(5-ASA)agents remain the mainstay treatment in ulcerative colitis(UC).A number of oral 5-ASA agents are commercially available,including azobond pro-drugs,as well as delayed-and controlledrelease form... 5-aminosalicylate(5-ASA)agents remain the mainstay treatment in ulcerative colitis(UC).A number of oral 5-ASA agents are commercially available,including azobond pro-drugs,as well as delayed-and controlledrelease forms of mesalazine.However,poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC.Recently, new,once-daily formulations of mesalazine,including the unique multi-matrix delivery system and mesalazine granules,were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC,with a good safety profile comparable to that of other oral mesalazine formulations.In addition,they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical practice.This editorial summarizes the available literature on the short-and medium-term efficacy and safety of the new once-daily mesalazine formulations. 展开更多
关键词 Ulcerative colitis 5-aminosalicylate MESALAZINE Multi matrix system Therapy ONCE-DAILY Compliance
下载PDF
5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro 被引量:2
12
作者 Hai-Ming Fang Qiao Mei +1 位作者 Jian-Ming Xu Wei-Juan Ma 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第20期2872-2877,共6页
AIM: To investigate the effects of 5-aminosalicylic acid (5-ASA) in combination with nimesulide on the proliferation of HT-29 colon carcinoma cells and its potential mechanisms. METHODS: Inhibitory effects of drugs (5... AIM: To investigate the effects of 5-aminosalicylic acid (5-ASA) in combination with nimesulide on the proliferation of HT-29 colon carcinoma cells and its potential mechanisms. METHODS: Inhibitory effects of drugs (5-ASA,nimesulide and their combination) on HT-29 colon carcinoma cells were investigated by thiazolyl blue tetrazolium bromide (MTT) assay. Cellular apoptosis and proliferation were detected by TUNEL assay and immunocytochemical staining,respectively. RESULTS: Pretreatment with 5-ASA or nimesulide at the concentration of 10-1000 μmol/L inhibited proliferation of HT-29 colon carcinoma cells in a dose-dependent manner in vitro (t = 5.122,P < 0.05; t = 3.086,P < 0.05,respectively). The inhibition rate of HT-29 colon carcinoma cell proliferation was also increased when pretreated with 5-ASA (100 μmol/L) or nimesulide (100 μmol/L) for 12-96 h,which showed an obvious time-effect relationship (t = 6.149,P < 0.05; t = 4.159,P < 0.05,respectively). At the concentration of 10-500 μmol/L,the apoptotic rate of HT-29 colon carcinoma cells significantly increased (t = 18.156,P < 0.001; t = 19.983,P < 0.001,respectively),while expression of proliferating cell nuclear antigen (PCNA) was remarkably decreased (t = 6.828,P < 0.05; t = 14.024,P < 0.05,respectively). 5-ASA in combination with nimesulide suppressed the proliferation of HT-29 colon carcinoma cells more than either of these agents in a dose-dependent and time-dependent manner (t = 5.448,P < 0.05; t = 4.428,P < 0.05,respectively). CONCLUSION: 5-ASA and nimesulide may inhibit the proliferation of HT-29 colon carcinoma cells and coadministration of these agents may have additional chemopreventive potential. 展开更多
关键词 Colorectal cancer 5-aminosalicylic acid NIMESULIDE
下载PDF
A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy 被引量:1
13
作者 Deepak Parakkal Eli D Ehrenpreis +2 位作者 Matthew P Thorpe Karson S Putt Bruce Hannon 《World Journal of Gastroenterology》 SCIE CAS CSCD 2010年第1期136-137,共2页
New once daily mesalamine formulations may improve adherence to medication usage.Response to Asacol and other forms of 5-aminosalicyclic acid(5-ASA)is better correlated with tissue concentrations and best predicted by... New once daily mesalamine formulations may improve adherence to medication usage.Response to Asacol and other forms of 5-aminosalicyclic acid(5-ASA)is better correlated with tissue concentrations and best predicted by concentrations of the drug within the lumen of the colon.Our group used computer simulation to predict colonic 5-ASA levels after Asacol administration.In our study,the model simulated Asacol distribution in the healthy colon,and during quiescent and active ulcerative colitis.An Asacol dosage of 800 mg,threetimes a day,was compared to 2400 mg given once a day.Under ideal conditions,the predicted maximum drug in the total colon and individual colonic segments over 100 d differed by less than 3%between single and multiple doses.Despite changes in motility and defection rates,the predicted maximum and average 5-ASA concentrations in the total colon and individual colonic segments differed by less than 10%between dosing regimens.Asymmetric distribution of 5-ASA in the colon was influenced by frequency of bowel movements and colonic transit rate.In active colitis,sigmoid 5-ASA concentration becomes negligible.Our model supports once daily administration of Asacol as standard treatment for ulcerative colitis. 展开更多
关键词 Ulcerative colitis 5-aminosalicylate MESALAZINE Asacol ONCE-DAILY
下载PDF
Synthesis,Crystal Structure and Properties of a Zinc(Ⅱ) Complex Based on 5-(1H-Tetrazol-5-yl)isophthalic Acid Ligand 被引量:3
14
作者 张兴晶 王璐瑶 +3 位作者 尉兵 李梦 乔宇 车广波 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 2016年第8期1213-1221,共9页
A novel polymeric zinc(II) complex {[Zn2(TIA)(H2O)3]·(NO3)}n(1, H3TIA = 5-(1H-tetrazol-5-yl)isophthalic acid) has been synthesized in mixed solvents under solvothermal conditions and characterized by ... A novel polymeric zinc(II) complex {[Zn2(TIA)(H2O)3]·(NO3)}n(1, H3TIA = 5-(1H-tetrazol-5-yl)isophthalic acid) has been synthesized in mixed solvents under solvothermal conditions and characterized by elemental analysis, IR spectroscopy and X-ray single-crystal diffraction. Complex 1 crystallizes in orthorhombic, space group Cmcm with a = 10.4210(6), b =23.3526(14), c = 6.9214(4)A, V = 1684.37(17)A^3, Z = 4, C9H4N5O(10)Zn2, Mr = 472.91, Dc = 1.865g/cm^3, F(000) = 932, λ(MoK α) = 2.909 mm^-1, R = 0.0423 and wR = 0.1287. The complex has good thermal stability and excellent photoluminescent property. 展开更多
关键词 zinc(Ⅱ) complex crystal structure 5-(1H-tetrazol-5-yl)isophthalic acid photoluminescence
下载PDF
Duration of treatment with 5-aminosalicylic acid compounds 被引量:1
15
作者 T Moshkovska JF Mayberry 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第32期4310-4315,共6页
The development of 5-aminosalicylic acid (5-ASA) therapy as a life long treatment for ulcerative colitis is reviewed from its origins in the 1940s to the present day. The drug was designed to treat rheumatoid arthriti... The development of 5-aminosalicylic acid (5-ASA) therapy as a life long treatment for ulcerative colitis is reviewed from its origins in the 1940s to the present day. The drug was designed to treat rheumatoid arthritis,but was found helpful in the management of nine patients with ulcerative colitis. This discovery preceded the emergence of the clinical trial as a tool for assessing a new drug's efficacy; as a result it lacked scientific rigour and was selective in its presentation of results. Nevertheless it identified the future cornerstone of therapy in ulcerative colitis. In 1962,the first double blind controlled trial of sulphasalazine was conducted on 40 patients. Outcome measures were subjective and included symptoms and an assessment of the rectal mucosa. In 1973,the first two papers on the role of sulphasalazine in maintenance of remission were published. Both used placebo controls and had a stratified design. Outcomes were measured using "an intention to treat" approach. The British study of 64 patients used both subjective and objective criteria to assess outcomes. Patients on placebo had a relapse rate four times patients on active treatment and this founded the basis for a life long approach to therapy with 5-ASA compounds in ulcerative colitis. However,in 1985,a small "on demand" study of 32 patients suggested this approach might be as effective as continuous treatment. Some support for this view came from an Italian study which showed no benefit to continued treatment for those in remission for two years or more. The central problem these studies identify is that of adherence to treatment in the long-term. Few studies have considered patients' attitudes to continuous therapy and it is an area that needs further investigation. 展开更多
关键词 Ulcerative colitis 5-aminosalicylic acid compounds Sulphasalazine mesalazine adherance trials
下载PDF
A porous puckered V_(2)O_(5) polymorph as new high performance cathode material for aqueous rechargeable zinc batteries 被引量:1
16
作者 Dauren Batyrbekuly Barbara Laïk +2 位作者 Jean-Pierre Pereira-Ramos Zhumabay Bakenov Rita Baddour-Hadjean 《Journal of Energy Chemistry》 SCIE EI CAS CSCD 2021年第10期459-468,I0012,共11页
Aqueous rechargeable zinc batteries are getting increasing attention for large-scale energy storage owing to their advantages in terms of cost,environmental friendliness and safety.Here,the layered puckeredγ’-V_(2)O... Aqueous rechargeable zinc batteries are getting increasing attention for large-scale energy storage owing to their advantages in terms of cost,environmental friendliness and safety.Here,the layered puckeredγ’-V_(2)O_(5) polymorph with a porous morphology is firstly introduced as cathode for an aqueous zinc battery system in a binary Zn^(2+)/Li^(+)electrolyte.The Zn‖γ’-V_(2)O_(5) cell delivers high capacities of 240 and190 mAh g^(-1) at current densities of 29 and 147 mA g^(-1),respectively,and remarkable cycling stability in the 1.6 V-0.7 V voltage window(97%retention after 100 cycles at 0.15 A g^(-1)).The detailed structural evolution during first discharge-charge and subsequent cycling is investigated using X-ray diffraction and Raman spectroscopy.We demonstrate a reaction mechanism based on a selective Li insertion in the1.6 V-1.0 V voltage range.It involves a reversible exchange of 0.8 Li^(+)in γ’-V_(2)O_(5) and the same structural response as the one reported in lithiated organic electrolyte.However,in the extended 1.6 V-0.7 V voltage range,this work puts forward a concomitant and gradual phase transformation from γ’-V_(2)O_(5) to zinc pyrovanadate Zn_(3)V_(2)O_(7)(OH)2.2 H_(2)O(ZVO)during cycling.Such mechanism involving the in-situ formation of ZVO,known as an efficient Zn and Li intercalation material,explains the high electrochemical performance here reported for the Zn‖γ’-V_(2)O_(5) cell.This work highlights the peculiar layered-puckeredγ’-V_(2)O_(5) polymorph outperforms the conventionalα-V_(2)O_(5) with a huge improvement of capacity of 240 mAh g^(-1)vs 80 mAh g^(-1) in the same electrolyte and voltage window. 展开更多
关键词 Vanadium pentoxide γ-V_(2)O_(5) Cathode Aqueous zinc battery High performance Layered structure Energy storage Renewable energy
下载PDF
Zinc chloride catalyzed synthesis of 5-substituted 1H-tetrazoles under solvent free condition
17
作者 Shahnaz Rostamizadeh Hamid Ghaieni +1 位作者 Reza Aryan Ali Amani 《Chinese Chemical Letters》 SCIE CAS CSCD 2009年第11期1311-1314,共4页
Zinc chloride is an efficient and safe catalyst in the [3 + 2] cycloaddition reaction of organic nitriles with sodium azide in solventless condition. The corresponding 5-substituted ^1H tetrazoles were obtained under... Zinc chloride is an efficient and safe catalyst in the [3 + 2] cycloaddition reaction of organic nitriles with sodium azide in solventless condition. The corresponding 5-substituted ^1H tetrazoles were obtained under mild conditions. This method can overcome disadvantages such as: the use of toxic metals and expensive reagents, drastic reaction conditions, water sensitivity and the presence of dangerous hydrazoic acid. 展开更多
关键词 5-Substituted ^1H-tetrazoles zinc chloride Sodium azide Solvent free
下载PDF
Colon-specific drug delivery systems based on cyclodextrin prod rugs: In vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates
18
作者 Mei-Juan Zou Gang Cheng +4 位作者 Hirokazu Okamoto Xiu-Hua Hao Feng An Fu-De Cui Kazumi Danjo 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第47期7457-7460,共4页
AIM: To investigate the release of cyclodextrin-S-amino- salicylic acid (CyD-S-ASA) in cecum and colon. METHODS: An anti-inflammatory drug 5-ASA was conjugated onto the hydroxyl groups of α-, β- and γ-cydodextr... AIM: To investigate the release of cyclodextrin-S-amino- salicylic acid (CyD-S-ASA) in cecum and colon. METHODS: An anti-inflammatory drug 5-ASA was conjugated onto the hydroxyl groups of α-, β- and γ-cydodextrins (CyDs) through an ester linkage, and the in vivo drug release behavior of these prodrugs in rat' s gastrointestinal tract after the oral administration was investigated. RESULTS: The 5-ASA concentration in the rat's stomach and small intestine after the oral administration of CyD- 5-ASA conjugate was much lower than that after the oral administration of 5-ASA alone. The lower concentration was attributable to the passage of the conjugate through the stomach and small intestine without significant degradation or absorption, followed by the degradation of the conjugate site-specific in the cecum and colon. The oral administration of CyD-S-ASA resulted in lower plasma and urine concentration of 5-ASA than that of 5-ASA alone. CONCLUSION: CyD-5-ASA conjugates may be used as prodrugs for colon-specific drug delivery system. 展开更多
关键词 CYCLODEXTRIN 5-aminosalicylic acid In vivo COLON-SPECIFIC
下载PDF
Can 5-aminosalicylic acid suppository decrease the pain after rectal band ligation?
19
作者 Burcak Kayhan Digdem Ozer +2 位作者 Meral Akdogan Ersan Ozaslan Osman Yuksel 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第22期3523-3525,共3页
AIM: To investigate the effect of 5-aminosalicylic acid (5-ASA) suppositories on rectal band ligation-induced pain. METHODS: Sixty patients were randomized into two treatment groups. RESULTS: Our results showed that t... AIM: To investigate the effect of 5-aminosalicylic acid (5-ASA) suppositories on rectal band ligation-induced pain. METHODS: Sixty patients were randomized into two treatment groups. RESULTS: Our results showed that there was no difference between 5-ASA suppository group and the control group for pain control. CONCLUSION: 5-ASA may be an alternative treatment for hemorrhoids; however, it does not affect the rectal band ligation-induced pain. 展开更多
关键词 HEMORRHOID PAIN 5-aminosalicylic acid Rectal band ligation
下载PDF
缺陷型ZSM-5沸石金属改性特征
20
作者 王吉垒 孙博 +2 位作者 林龙 周琳 李佩儒 《当代化工》 CAS 2024年第9期2017-2020,共4页
MFI沸石中普遍存在骨架缺陷。但由于某些原因,迄今为止人们仅对于S-1沸石的骨架缺陷进行了一些较为系统的研究。实际上,与S-1沸石同样具有MFI拓扑结构的ZSM-5沸石也普遍存在不同程度的骨架缺陷。这些骨架缺陷会使ZSM-5沸石产生不同数量... MFI沸石中普遍存在骨架缺陷。但由于某些原因,迄今为止人们仅对于S-1沸石的骨架缺陷进行了一些较为系统的研究。实际上,与S-1沸石同样具有MFI拓扑结构的ZSM-5沸石也普遍存在不同程度的骨架缺陷。这些骨架缺陷会使ZSM-5沸石产生不同数量和形式的羟基窝缺陷位。然而,关于羟基窝对缺陷型ZSM-5沸石物化性质的研究却鲜有报道,所以有必要对缺陷型ZSM-5沸石中羟基窝的物化性质进行系统研究。因此,研究了缺陷型ZSM-5沸石的金属离子改性规律,考察羟基窝对金属离子在缺陷型HZSM-5上的改性行为,以便为将来开发利用缺陷型ZSM-5沸石打下基础。 展开更多
关键词 ZSM-5沸石 羟基窝 锌离子 骨架缺陷 金属改性
下载PDF
上一页 1 2 15 下一页 到第
使用帮助 返回顶部